Press releases

2019

2019-11-05 13:15 Nanologica to attend BIO-Europe Nov. 11-13 in Hamburg for partnering discussions

Nanologica’s drug delivery platform NLAB Silica™ consists of nanoporous amorphous proprietary silica particles. By loading the API in NLAB...

2019-10-24 09:53 Nouryon Nordic prize winner Dr Sabrina Valetti

Dr Valetti conducted her research on mesoporous silica particles at Nanologica AB during 2014-2016, as recipient of the prestigious Marie Curie Post Doc...

2019-10-17 07:51 Nanologica’s collaboration project prolonged Regulatory MAR

The agreement between Nanologica and AstraZeneca for the evaluation of Nanologica’s pending patented technology applied to AstraZeneca materials...

2019-10-02 09:55 Start of process for preparing investigational medication for NIC-001

English translation NIC-001 is Nanologica’s sublingual formulation of metoclopramide for treating gastroparesis patients. The process for preparing...

2019-09-03 12:46 Large potential for Nanologica's product for the treatment of gastroparesis Regulatory MAR

After regulatory investigations and an extended market analysis, Nanologica advances the project NIC-001 towards clinical phase IIa. The market analysis...

2019-08-20 12:39 Start of large-scale production of silica

Large-scale production of Nanologica’s silica has now started at the contract manufacturer Sterling Pharma Solutions Ltd. in Newcastle, United Kingdom...

2019-07-02 12:33 Nanologica starts business within preparative chromatography with profitable agreement Regulatory MAR

Nanologica enters into an agreement with Chinese Yunbo Technology (Beijing) Co. for the delivery of preparative chromatography media to a value of approximately...

2019-04-30 12:16 Nanologica's patent issued in the USA

Nanologica announces that the United States Patent and Trademark Office has issued Nanologica’s patent titled ”Improved method for stem cell...

2019-03-08 12:09 Nanologica to attend BIO-Europe 2019, Mar 25-27 in Vienne for partnering Discussions

Nanologica will be attending BIO-Europe Spring 2019 in Vienna, Mar. 25 – 27 to meet with potential pharmaceutical partners regarding co-development...

2019-01-30 12:02 Nanologica and AstraZeneca joint evaluation project

Nanologica and AstraZeneca have entered into an agreement for the evaluation of Nanologica’s pending patented technology, applied to AstraZeneca...

Previous Next

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.

Press releases

Read more:

Categories

2019